Sanofi Pasteur Biologics, LLC — Federal Contractor Profile
SANOFI PASTEUR BIOLOGICS, LLC: $27.38 Billion in Federal Vaccine and Biologics Contracts
Contractor Overview
Total Contract Value: $27,375,505,919 ($27.4B)
Total Awards: 103
Company Profile
SANOFI PASTEUR BIOLOGICS, LLC is a significant player in the federal government's biopharmaceutical sector, with a total contract value of $27.38 billion over 103 contracts. The company specializes in the development, production, and distribution of vaccines and biologics, which are critical for public health and national security. Their core capabilities include advanced manufacturing processes, clinical research, and supply chain management. The contractor has a diverse portfolio, serving multiple agencies, but there is a notable concentration on the Department of Health and Human Services (HHS). The company's track record includes several high-profile contracts, such as those for pandemic influenza vaccines and biodefense products. Their business strategy appears to focus on maintaining strong relationships with key agencies and leveraging their expertise in biologics to secure competitive contracts. SANOFI PASTEUR BIOLOGICS, LLC is a dominant player in the federal biopharmaceutical market, with a strong track record and a focus on innovation and reliability.
Specializations
- Vaccines
- Biologics
- Pandemic Preparedness
- Biodefense
- Clinical Research
- Advanced Manufacturing
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 100% (all contracts are competitive)
Agency Concentration: moderate
Growth Trajectory: expanding
Sole Source Rate: 0%
Recompete Rate: 80% (indicating a high rate of contract renewals)
Competitive Position
SANOFI PASTEUR BIOLOGICS, LLC is a dominant player in the federal biopharmaceutical market, with a strong track record and a focus on innovation and reliability. The company's expertise in advanced manufacturing and clinical research positions it as a key supplier for agencies such as the Department of Health and Human Services (HHS) and the Department of Defense (DOD). Their ability to secure competitive contracts and maintain high recompete rates indicates a strong market position and a robust business strategy.
Value to Taxpayers
SANOFI PASTEUR BIOLOGICS, LLC provides significant value to taxpayers through its critical role in public health and national security. Their contracts for vaccines and biologics are essential for pandemic preparedness and biodefense. The company's consistent performance and competitive pricing, as evidenced by their high recompete rate, suggest that they are delivering high-quality products at a reasonable cost.
Agency Relationships
The Department of Health and Human Services (HHS) is the primary client for SANOFI PASTEUR BIOLOGICS, LLC, with a significant portion of their contracts. This concentration poses a dependency risk, as the company's financial health is closely tied to the performance and funding of HHS programs. However, the company's strong relationships with other agencies, such as the Department of Defense (DOD), provide a diversified client base and reduce overall dependency risks.
Red Flags
- High concentration on HHS: The company's significant reliance on HHS contracts could pose a risk if there are funding or policy changes that affect these programs.
- No sole-source contracts: The absence of sole-source contracts suggests that the company is not leveraging its expertise to secure exclusive contracts, which could indicate a lack of differentiation in the market.
- Moderate agency concentration: While the company has a diverse portfolio, the concentration on HHS and DOD could lead to dependency risks.
Green Flags
- High recompete rate: The company's strong performance and consistent quality have led to a high rate of contract renewals, indicating customer satisfaction and reliability.
- Diverse portfolio: The company's contracts span multiple agencies, providing a diversified client base and reducing dependency on any single agency.
- Competitive contracts: All contracts are competitive, suggesting that the company is maintaining a strong market position and leveraging its expertise to secure contracts through competition.
Key Contracts
SANOFI PASTEUR BIOLOGICS, LLC has secured several high-profile contracts, including those for pandemic influenza vaccines and biodefense products. For example, the company has been awarded multiple contracts to produce and distribute pandemic influenza vaccines, which are critical for public health preparedness. These contracts not only demonstrate the company's expertise in vaccine production but also highlight their commitment to public health and national security. Additionally, the company's contracts for biodefense products, such as anthrax vaccines, underscore their role in national security. These contracts reveal the company's capabilities in advanced manufacturing, clinical research, and supply chain management, as well as their strategic focus on maintaining strong relationships with key agencies.
Frequently Asked Questions
What does SANOFI PASTEUR BIOLOGICS, LLC do for the federal government?
SANOFI PASTEUR BIOLOGICS, LLC specializes in the development, production, and distribution of vaccines and biologics. They provide critical support for public health and national security, including pandemic influenza vaccines, biodefense products, and advanced manufacturing services. Their core capabilities include advanced manufacturing processes, clinical research, and supply chain management.
How much taxpayer money does SANOFI PASTEUR BIOLOGICS, LLC receive?
SANOFI PASTEUR BIOLOGICS, LLC has received a total of $27.38 billion in federal contracts over 103 contracts. The average contract size is $265,781,611, indicating a significant investment in the company's biopharmaceutical capabilities. The company's contracts span multiple agencies, including the Department of Health and Human Services (HHS) and the Department of Defense (DOD).
Is SANOFI PASTEUR BIOLOGICS, LLC good value for taxpayer money?
SANOFI PASTEUR BIOLOGICS, LLC provides significant value to taxpayers through its critical role in public health and national security. Their contracts for vaccines and biologics are essential for pandemic preparedness and biodefense. The company's consistent performance and competitive pricing, as evidenced by their high recompete rate, suggest that they are delivering high-quality products at a reasonable cost. However, the high concentration on HHS contracts poses a dependency risk, and the company's lack of sole-source contracts could indicate a lack of differentiation in the market.
How does SANOFI PASTEUR BIOLOGICS, LLC win its contracts?
SANOFI PASTEUR BIOLOGICS, LLC wins its contracts through a combination of competitive bidding and strong relationships with key agencies. The company's expertise in advanced manufacturing, clinical research, and supply chain management positions it as a preferred supplier for agencies such as the Department of Health and Human Services (HHS) and the Department of Defense (DOD). Their consistent performance and high recompete rate indicate that they are maintaining a strong market position and leveraging their expertise to secure contracts through competition.
What agencies use SANOFI PASTEUR BIOLOGICS, LLC most?
The Department of Health and Human Services (HHS) is the primary client for SANOFI PASTEUR BIOLOGICS, LLC, with a significant portion of their contracts. This concentration poses a dependency risk, as the company's financial health is closely tied to the performance and funding of HHS programs. However, the company's strong relationships with other agencies, such as the Department of Defense (DOD), provide a diversified client base and reduce overall dependency risks.
What are the risks of relying on SANOFI PASTEUR BIOLOGICS, LLC?
The primary risk of relying on SANOFI PASTEUR BIOLOGICS, LLC is the high concentration on HHS contracts, which could pose a risk if there are funding or policy changes that affect these programs. Additionally, the company's lack of sole-source contracts suggests that they are not leveraging their expertise to secure exclusive contracts, which could indicate a lack of differentiation in the market. However, the company's strong performance and consistent quality have led to a high rate of contract renewals, indicating customer satisfaction and reliability.
How does SANOFI PASTEUR BIOLOGICS, LLC compare to similar contractors?
SANOFI PASTEUR BIOLOGICS, LLC is a dominant player in the federal biopharmaceutical market, with a strong track record and a focus on innovation and reliability. The company's expertise in advanced manufacturing and clinical research positions it as a key supplier for agencies such as the Department of Health and Human Services (HHS) and the Department of Defense (DOD). Their ability to secure competitive contracts and maintain high recompete rates indicates a strong market position and a robust business strategy. However, the company's lack of sole-source contracts and high concentration on HHS contracts could indicate a need for diversification and differentiation in the market.
Recent Federal Contracts
Sanofi Pasteur Biologics, LLC has 7 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| HHS awarded $349M to Sanofi Pasteur for vaccine production, raising questions... | Department of Health and Human Services | $348.9M | N/A |
| NIH awards $55.1M to Sanofi Pasteur for MVA vaccine R&D, spanning over a decade. | Department of Health and Human Services | $55.1M | N/A |
| HHS awarded $36.6M for licensed smallpox vaccine, with Sanofi Pasteur Biologi... | Department of Health and Human Services | $36.6M | N/A |
| HHS awarded $35.37M for smallpox vaccine manufacturing to Sanofi Pasteur, a s... | Department of Health and Human Services | $35.4M | N/A |
| HHS awarded $29.8M for vaccine development, but competition was limited. | Department of Health and Human Services | $29.8M | N/A |
| HHS Awards $29M for Smallpox Vaccine to Sanofi Pasteur, Limited Competition | Department of Health and Human Services | $29.1M | N/A |
| HHS Awards $28.17M for Smallpox Vaccine, Sole-Source Contract Raises Concerns | Department of Health and Human Services | $28.2M | N/A |